On August 10, the White House issued an executive order redefining the U.S. national childhood vaccination schedule: it reduces from 18 to 11 the diseases for which a vaccine is universally recommended, and shifts the remainder to a model of shared clinical decision-making between parents and physicians.
The measure revives changes that Health Secretary Robert F. Kennedy Jr. announced this year, which a federal court blocked in March for failing to follow administrative procedures, according to CIDRAP, the University of Minnesota's Center for Infectious Disease Research and Policy. The order instructs the Centers for Disease Control and Prevention (CDC) to align the immunization calendar with a December 2025 scientific report that compared the U.S. schedule with those of peer countries such as Denmark. For Mexico, the move carries relevance as a signal of institutional design: a North American government is redefining where authority over vaccine recommendations resides, an axis upheld in Mexico by the Cartilla Nacional de Vacunación and the CENSIA schedule.
The new schedule retains universal recommendations for vaccines against measles, mumps, rubella, diphtheria, tetanus, whooping cough, polio, Haemophilus influenzae type B, pneumococcus, HPV, and chickenpox. Vaccines for Covid, rotavirus, influenza, hepatitis A, hepatitis B, and bacterial meningitis move to shared clinical decision-making, while those for RSV, dengue, and two types of bacterial meningitis are reserved for high-risk groups, as detailed by NBC News. The order also suggests separating the combined measles, mumps, and rubella (MMR) vaccine into three individual doses and administering vaccines at separate medical visits. On the question of a split MMR, the CDC noted that no individually FDA-approved versions exist and that no published evidence supports a clinical benefit from separating them.
The order sets a 90-day deadline for the Department of Health to present options for separate administration of the MMR vaccine, returning the issue to the agenda in early November. The next indicator to watch: how the CDC and its advisory committee respond, with their meeting schedule still pending.
This article was drafted with artificial intelligence assistance based on verified sources and reviewed by a human editor before publication.